Not the same thing: metastatic PTCs have a different background than ATCs

Dario de Biase, Federica Torricelli, Moira Ragazzi, Benedetta Donati, Elisabetta Khun, Michela Visani, Giorgia Acquaviva, Annalisa Pession, Giovanni Tallini, Simonetta Piana, Alessia Ciarrocchi

Research output: Contribution to journalArticle

Abstract

Anaplastic thyroid cancer (ATC) is a rare but highly aggressive form of thyroid cancer. By contrast, differentiated Papillary Thyroid Cancer (PTC) only rarely behave aggressively and develop distant metastasis. Whether distantly metastatic PTC (DM-PTC) and ATC share a common genetic background is still to be defined. We used a Next Generation Sequencing (NGS) to explore the genetic background of a cohort of ATC and DM-PTC and a group of well-differentiated PTC that did not developed distant metastasis as control (ctrl-PTC). A panel of 128 amplicons within 21 thyroid cancer related genes was analyzed in a set of 151 thyroid cancer samples including 66 ATCs and DM-PTCs. We showed that the ATC/DM-PTC group had an overall mutational load higher than ctrl-PTCs and that ATCs and DM-PTCs are characterized by a different genetic background, with the exception of mutations in the TERT promoter that were overrepresented in both ATCs (61.1%) and DM-PTCs (48.2%) versus non aggressive ctrl-PTCs (7.6%). In ATCs, TERT promoter mutations were frequently associated with p53 mutations, while in the DM-PTCs no significant co-occurrence was observed. No significant association of MED12 mutations with aggressiveness of thyroid cancer was observed in our analysis. Finally, correlation analysis showed that increasing number of mutations negatively impact on patient overall survival also within the ATC and DM-PTC group. Overall our analysis further highlights the relevance of TERT promoter mutations in driving aggressiveness and provides new pieces of information in the definition of aggressiveness evolution of thyroid cancer lesions.

Original languageEnglish
JournalEndocrine Connections
DOIs
Publication statusE-pub ahead of print - Nov 1 2018

Fingerprint

Factor IX
Thyroid Neoplasms
Mutation
Neoplasm Metastasis
Neoplasm Genes
Anaplastic Thyroid Carcinoma
Survival
Papillary Thyroid cancer

Cite this

Not the same thing : metastatic PTCs have a different background than ATCs. / de Biase, Dario; Torricelli, Federica; Ragazzi, Moira; Donati, Benedetta; Khun, Elisabetta; Visani, Michela; Acquaviva, Giorgia; Pession, Annalisa; Tallini, Giovanni; Piana, Simonetta; Ciarrocchi, Alessia.

In: Endocrine Connections, 01.11.2018.

Research output: Contribution to journalArticle

de Biase, D, Torricelli, F, Ragazzi, M, Donati, B, Khun, E, Visani, M, Acquaviva, G, Pession, A, Tallini, G, Piana, S & Ciarrocchi, A 2018, 'Not the same thing: metastatic PTCs have a different background than ATCs', Endocrine Connections. https://doi.org/10.1530/EC-18-0386
de Biase D, Torricelli F, Ragazzi M, Donati B, Khun E, Visani M et al. Not the same thing: metastatic PTCs have a different background than ATCs. Endocrine Connections. 2018 Nov 1. https://doi.org/10.1530/EC-18-0386
de Biase, Dario ; Torricelli, Federica ; Ragazzi, Moira ; Donati, Benedetta ; Khun, Elisabetta ; Visani, Michela ; Acquaviva, Giorgia ; Pession, Annalisa ; Tallini, Giovanni ; Piana, Simonetta ; Ciarrocchi, Alessia. / Not the same thing : metastatic PTCs have a different background than ATCs. In: Endocrine Connections. 2018.
@article{1ac618fecec845df937f79c6fbaabadb,
title = "Not the same thing: metastatic PTCs have a different background than ATCs",
abstract = "Anaplastic thyroid cancer (ATC) is a rare but highly aggressive form of thyroid cancer. By contrast, differentiated Papillary Thyroid Cancer (PTC) only rarely behave aggressively and develop distant metastasis. Whether distantly metastatic PTC (DM-PTC) and ATC share a common genetic background is still to be defined. We used a Next Generation Sequencing (NGS) to explore the genetic background of a cohort of ATC and DM-PTC and a group of well-differentiated PTC that did not developed distant metastasis as control (ctrl-PTC). A panel of 128 amplicons within 21 thyroid cancer related genes was analyzed in a set of 151 thyroid cancer samples including 66 ATCs and DM-PTCs. We showed that the ATC/DM-PTC group had an overall mutational load higher than ctrl-PTCs and that ATCs and DM-PTCs are characterized by a different genetic background, with the exception of mutations in the TERT promoter that were overrepresented in both ATCs (61.1{\%}) and DM-PTCs (48.2{\%}) versus non aggressive ctrl-PTCs (7.6{\%}). In ATCs, TERT promoter mutations were frequently associated with p53 mutations, while in the DM-PTCs no significant co-occurrence was observed. No significant association of MED12 mutations with aggressiveness of thyroid cancer was observed in our analysis. Finally, correlation analysis showed that increasing number of mutations negatively impact on patient overall survival also within the ATC and DM-PTC group. Overall our analysis further highlights the relevance of TERT promoter mutations in driving aggressiveness and provides new pieces of information in the definition of aggressiveness evolution of thyroid cancer lesions.",
author = "{de Biase}, Dario and Federica Torricelli and Moira Ragazzi and Benedetta Donati and Elisabetta Khun and Michela Visani and Giorgia Acquaviva and Annalisa Pession and Giovanni Tallini and Simonetta Piana and Alessia Ciarrocchi",
year = "2018",
month = "11",
day = "1",
doi = "10.1530/EC-18-0386",
language = "English",
journal = "Endocrine Connections",
issn = "2049-3614",
publisher = "BioScientifica Ltd.",

}

TY - JOUR

T1 - Not the same thing

T2 - metastatic PTCs have a different background than ATCs

AU - de Biase, Dario

AU - Torricelli, Federica

AU - Ragazzi, Moira

AU - Donati, Benedetta

AU - Khun, Elisabetta

AU - Visani, Michela

AU - Acquaviva, Giorgia

AU - Pession, Annalisa

AU - Tallini, Giovanni

AU - Piana, Simonetta

AU - Ciarrocchi, Alessia

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Anaplastic thyroid cancer (ATC) is a rare but highly aggressive form of thyroid cancer. By contrast, differentiated Papillary Thyroid Cancer (PTC) only rarely behave aggressively and develop distant metastasis. Whether distantly metastatic PTC (DM-PTC) and ATC share a common genetic background is still to be defined. We used a Next Generation Sequencing (NGS) to explore the genetic background of a cohort of ATC and DM-PTC and a group of well-differentiated PTC that did not developed distant metastasis as control (ctrl-PTC). A panel of 128 amplicons within 21 thyroid cancer related genes was analyzed in a set of 151 thyroid cancer samples including 66 ATCs and DM-PTCs. We showed that the ATC/DM-PTC group had an overall mutational load higher than ctrl-PTCs and that ATCs and DM-PTCs are characterized by a different genetic background, with the exception of mutations in the TERT promoter that were overrepresented in both ATCs (61.1%) and DM-PTCs (48.2%) versus non aggressive ctrl-PTCs (7.6%). In ATCs, TERT promoter mutations were frequently associated with p53 mutations, while in the DM-PTCs no significant co-occurrence was observed. No significant association of MED12 mutations with aggressiveness of thyroid cancer was observed in our analysis. Finally, correlation analysis showed that increasing number of mutations negatively impact on patient overall survival also within the ATC and DM-PTC group. Overall our analysis further highlights the relevance of TERT promoter mutations in driving aggressiveness and provides new pieces of information in the definition of aggressiveness evolution of thyroid cancer lesions.

AB - Anaplastic thyroid cancer (ATC) is a rare but highly aggressive form of thyroid cancer. By contrast, differentiated Papillary Thyroid Cancer (PTC) only rarely behave aggressively and develop distant metastasis. Whether distantly metastatic PTC (DM-PTC) and ATC share a common genetic background is still to be defined. We used a Next Generation Sequencing (NGS) to explore the genetic background of a cohort of ATC and DM-PTC and a group of well-differentiated PTC that did not developed distant metastasis as control (ctrl-PTC). A panel of 128 amplicons within 21 thyroid cancer related genes was analyzed in a set of 151 thyroid cancer samples including 66 ATCs and DM-PTCs. We showed that the ATC/DM-PTC group had an overall mutational load higher than ctrl-PTCs and that ATCs and DM-PTCs are characterized by a different genetic background, with the exception of mutations in the TERT promoter that were overrepresented in both ATCs (61.1%) and DM-PTCs (48.2%) versus non aggressive ctrl-PTCs (7.6%). In ATCs, TERT promoter mutations were frequently associated with p53 mutations, while in the DM-PTCs no significant co-occurrence was observed. No significant association of MED12 mutations with aggressiveness of thyroid cancer was observed in our analysis. Finally, correlation analysis showed that increasing number of mutations negatively impact on patient overall survival also within the ATC and DM-PTC group. Overall our analysis further highlights the relevance of TERT promoter mutations in driving aggressiveness and provides new pieces of information in the definition of aggressiveness evolution of thyroid cancer lesions.

U2 - 10.1530/EC-18-0386

DO - 10.1530/EC-18-0386

M3 - Article

C2 - 30400028

JO - Endocrine Connections

JF - Endocrine Connections

SN - 2049-3614

ER -